OTC · Biotechnology

JW (Cayman) Therapeutics Co. Ltd (JWCTF) Stock

$0.20 +0.00% OTC: JWCTF Healthcare

JW (Cayman) Therapeutics Co. Ltd is a biopharmaceutical entity currently in the clinical development phase, dedicated to the discovery, manufacturing, and commercialization of advanced cell-based immunotherapeutic solutions.

Valuation

MetricValue
Price$0.20
Market Cap$84.22M
P/E Ratio-1.05
P/B Ratio1.03
P/S Ratio2.05
EPS (TTM)$-1.33
52-Week High$0.66
52-Week Low$0.20
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-75.15%
ROA-55.76%
ROCE-49.96%
Gross Margin43.15%
Operating Margin-105.50%
Net Margin-196.12%
Debt/Equity0.47
Current Ratio1.45

Annual Financials (USD)

Metric20212022202320242025
Revenue$31.0M$146.0M$174.0M$158.0M$276.0M
Operating Profit$-759.0M$-856.0M$-790.0M$-459.0M$-242.0M
Net Profit$-702.0M$-846.0M$-768.0M$-591.0M$-541.0M
EPS$-1.76$-2.06$-1.87$-1.43$-1.33
Op Margin-2464.8%-587.4%-454.2%-290.3%-87.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$3.1B$2.8B$2.1B$1.7B$987.0M
Total Liabilities$326.0M$437.0M$462.0M$511.0M$431.0M
Cash$1.8B$1.4B$1.0B$757.0M$503.0M
Borrowings$147.0M$279.0M$319.0M$422.0M$263.0M

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-561.0M$-537.0M$-398.0M$-333.0M$-77.0M
Investing Cash Flow$-210.0M$-201.0M$-5.0M$-31.0M$-3.0M
Financing Cash Flow$-18.0M$-23.0M$-27.0M$-28.0M$-25.0M
Net Cash Flow$-796.0M$-451.0M$-377.0M$-249.0M$-254.0M
Free Cash Flow$-634.0M$-614.0M$-413.0M$-349.0M$-78.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.16
EV / EBITDA-1.54
FCF Yield-13.61%
Quick Ratio1.29
Interest Coverage-58.05
Return 1Y-19.11%
Return 3Y-43.83%
Return 5Y—

Ownership

Insiders Held23.85%
Institutions Held0.33%
Institutions Float Held0.43%
Institutional HolderSharesReport Date
DFA INVESTMENT DIMENSIONS GROUP INC-Emerging Markets Core Eqy. 2 PORT.576,5002026-04-30
SPDR INDEX SHARES Fd.S-State Street SPDR S&P Emerging Markets Small Ca229,0002026-06-30
DFA INVESTMENT DIMENSIONS GROUP INC-World ex U.S. Core Eqy. PORT.105,5002026-04-30
SPDR INDEX SHARES FUNDS-State Street SPDR S&P China ETF82,0002026-06-30
DFA INVESTMENT DIMENSIONS GROUP INC-Emerging Markets Social Core Eqy. 61,5002026-04-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BRIBFBrii Biosciences Limited $0.13 +0.00% -2.71 $90.69M 0.00%
BXPHFBotanix Pharmaceuticals Limited $0.02 -30.23% -0.41 $29.89M 0.00%
GNFTFGenfit S.a. $15.95 +0.00% -8.14 $799.03M 0.00%
IPHYFInnate Pharma S.A. $1.65 +0.00% -2.84 $154.94M 0.00%
MLLCFMolecular Partners AG $3.80 +0.00% -2.13 $142.54M 0.00%

About JW (Cayman) Therapeutics Co. Ltd

JW (Cayman) Therapeutics Co. Ltd is a biopharmaceutical entity currently in the clinical development phase, dedicated to the discovery, manufacturing, and commercialization of advanced cell-based immunotherapeutic solutions. Its core mission is to combat both hematological cancers (blood cancers) and various solid tumors. The company's innovative treatments encompass cell-derived immunotherapies, particularly Chimeric Antigen Receptor T-cell (CAR-T) therapies, which leverage a patient's own immune cells to target and eliminate cancerous cells. Leading its clinical efforts is Carteyva (relmacabtagene autoleucel), an anti-CD19 CAR-T therapeutic agent aimed at various forms of blood cancer. Beyond its flagship product, JW (Cayman) Therapeutics maintains a promising product pipeline. This includes JWCAR129, an autologous CAR-T therapy for treating multiple myeloma; JWATM204, a T-cell receptor (TCR) T-cell therapy candidate for hepatocellular carcinoma (HCC); and JWATM203, another autologous T-cell therapy that mimics T-cell receptors, specifically designed to target alpha-fetoprotein in HCC. Established in 2016, JW (Cayman) Therapeutics Co. Ltd is headquartered in Shanghai, People's Republic of China.

JW (Cayman) Therapeutics Co. Ltd is headquartered in CN.

JW (Cayman) Therapeutics Co. Ltd (JWCTF) stock trades at $0.20 with a market capitalization of $84.22M. The stock is valued at a price-to-earnings (P/E) ratio of -1.05, price-to-book of 1.03, price-to-sales of 2.05. Over the past 52 weeks the stock has ranged between $0.20 and $0.66, and currently trades 69.7% below its 52-week high.

On profitability, JW (Cayman) Therapeutics Co. Ltd generates a return on equity (ROE) of -75.15%, return on capital employed of -49.96%, an operating margin of -105.50%, a net profit margin of -196.12%.

Official website: www.jwtherapeutics.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides